These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 28116835

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
    Buongiorno M, Antonelli F, Cámara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, Calopa M, Pascual-Sedano B, Campolongo A, Valldeoriola F, Tolosa E, Kulisevsky J, Martí MJ.
    Parkinsonism Relat Disord; 2015 Aug; 21(8):871-6. PubMed ID: 26003410
    [Abstract] [Full Text] [Related]

  • 5. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
    Olanow CW, Espay AJ, Stocchi F, Ellenbogen AL, Leinonen M, Adar L, Case RJ, Orenbach SF, Yardeni T, Oren S, Poewe W, 006 study group.
    J Parkinsons Dis; 2021 Aug; 11(1):177-186. PubMed ID: 33164945
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
    Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, Othman AA.
    AAPS J; 2013 Apr; 15(2):316-23. PubMed ID: 23229334
    [Abstract] [Full Text] [Related]

  • 10. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A, Nagy H, Wacha J, Bereczki D, Takáts A.
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [Abstract] [Full Text] [Related]

  • 11. Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
    Melgari JM, Salomone G, di Biase L, Marano M, Scrascia F, Di Lazzaro V.
    Parkinsonism Relat Disord; 2015 Mar; 21(3):327-8. PubMed ID: 25595317
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I, Santos-García D, Catalán MIJ, Puente V, Valldeoriola F, Grandas F, Mir P, Parra JC, Arbelo JM.
    J Parkinsons Dis; 2019 Mar; 9(1):173-182. PubMed ID: 30562907
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Medical treatment of Parkinson's disease.
    Ahlskog JE.
    Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inhaled levodopa (Inbrija) for Parkinson's disease.
    Med Lett Drugs Ther; 2019 May 20; 61(1572):73-74. PubMed ID: 31169799
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.